WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager

SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced an agreement with Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases.Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager ...